Possible new treatment SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

it looks like the phase-1 trial in humans was completed, but no data/results put out yet.

www.synergypharma.com/Pipeline_%26_Programs____SP-333.html

I do like that its action is topical and not systemic. Less chance of metabolic side effects.

Thanks for the heads up. This is a long way out because the only trials on humans was essentially a regression test and their next trial will also not include active disease subjects. Looking to the mice studies they do not mention if it corrected 100% of the DSS mice or 50% or 20% etc.

Nice to see companies working on better remedies for us.